Vaccines in prophylaxis of urinary tract infections caused by the bacteria from the genus Proteus.

Urinary tract infections (UTIs) pose a threat especially to women, the individuals with weakened immunity or with abnormalities in the urinary tract as well as to hospitalized and catheterized patients. The bacteria from the genus Proteus, especially P. mirabilis, are important UTI pathogenic factors. They frequently cause chronic, recurrent or severely complicated infections, resulting in the urinary stones production due to urease and other virulence factors. The ability to survive inside the stones and the increasing antibiotic resistance make it difficult to eradicate the bacteria from the urinary tract. A good solution to the problem may be the vaccination which obtained the interest from the surveyed persons, in spite of the antivaccination attitudes visible also in Poland. Currently, there are four vaccines available, composed of killed cells of different uropathogens, including Proteus spp. They are administrated intranassaly or vaginally and require many booster doses. They decrease the probability of reinfection in patients suffering from recurrent UTIs but the mechanisms of the immune response have not been exactly defined. Promising results were obtained in the studies on a mice model concerning the subunit, conjugated vaccines in which various P. mirabilis surface antigens (with the exception of flagellin) were successfully employed. Hitherto, the best results were obtained by the intranasal vaccinations, using MR/P fimbriae antigens with MPL or cholera toxin adjuvants and the antigens expressed in Lactococcus lactis or Salmonella Typhimurium. It led to an increase in the levels of the specific serum and mucosal antibodies resulting in the protection against P. mirabilis UTIs.